Recursion Pharmaceuticals, Inc. (RXRX)
4.12
+0.05
(+1.23%)
USD |
NASDAQ |
Oct 02, 16:00
4.12
0.00 (0.00%)
After-Hours: 20:00
Recursion Pharmaceuticals Gross Profit Margin (Quarterly) : -202.4% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -202.4% |
| March 31, 2026 | -289.2% |
| December 31, 2025 | 24.37% |
| September 30, 2025 | -442.7% |
| June 30, 2025 | -68.87% |
| March 31, 2025 | -127.4% |
| December 31, 2024 | -333.1% |
| September 30, 2024 | 37.97% |
| June 30, 2024 | 9.14% |
| March 31, 2024 | -5.60% |
| December 31, 2023 | -115.6% |
| September 30, 2023 | -35.55% |
| June 30, 2023 | 0.32% |
| Date | Value |
|---|---|
| March 31, 2023 | -3.84% |
| December 31, 2022 | 19.63% |
| September 30, 2022 | -17.67% |
| June 30, 2022 | -86.38% |
| March 31, 2022 | -47.67% |
| December 31, 2021 | -1.70% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Editas Medicine, Inc. | 96.50% |
| Amgen, Inc. | 72.08% |
| Halozyme Therapeutics, Inc. | 77.40% |
| Novavax, Inc. | 77.70% |
| AVITA Medical, Inc. | 81.87% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -51.51% |
| Return on Assets | -38.25% |
| Return on Invested Capital | -47.83% |
| Profit Margin (Quarterly) | -1.71K% |
| Operating Margin (Quarterly) | -1.76K% |
| Return on Net Operating Assets | -80.06% |